文献速递免疫规划传染病防控与疫情报告

在头对头试验中接种PCV10或PCV13的巴布亚新几内亚儿童肺炎球菌携带、血清型分布及抗菌药物敏感性

Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial.
PubMed 文献 · Vaccine · 2023-07-20

262名巴布亚新几内亚婴儿随机接种3剂PCV10或PCV13,9月龄时部分加种PPV或不加种。23月龄时PCV10组携带率93.6%、PCV13组88.6%,PCV10组PCV10血清型携带率19.8%高于PCV13组9.3%(p=0.049)。携带菌株对青霉素非敏感率45.6%(脑膜炎折点),对复方磺胺甲噁唑耐药常见。

要点

  • 23月龄时PCV10组携带率93.6%(95%CI 86.6-97.6%),PCV13组88.6%(95%CI 80.1-94.4%)。
  • PCV10组PCV10血清型携带率19.8%高于PCV13组9.3%(p=0.049)。
  • 携带菌株对青霉素非敏感率45.6%(脑膜炎折点MIC≥0.12 µg/mL),对复方磺胺甲噁唑 intermediate 耐药23.2%、完全耐药16.9%。

核心结论

  • 即使接种PCV10或PCV13后,巴布亚新几内亚等高危地区儿童仍持续高水平携带肺炎球菌,包括携带高度抗菌药物耐药的PCV血清型。

研究设计与样本

  • 头对头随机试验,262名婴儿随机接受3剂PCV10或PCV13(1-2-3月龄),9月龄时加种PPV或不加种;在1、4、9、10、23、24月龄采集鼻咽拭子培养。

主要发现

  • 1-23月龄采集的1063份鼻咽拭子中883份分离出肺炎球菌,包括820株可分型(64种血清型)和144株不可分型。
  • 23月龄时PCV10组携带率93.6%(95%CI 86.6-97.6%),PCV13组88.6%(95%CI 80.1-94.4%)。
  • PCV10组PCV10血清型携带率19.8%(95%CI 12.2-29.5)高于PCV13组9.3%(95%CI 4.1-17.3)(p=0.049)。
  • PCV10组与PCV13组之间、以及加种PPV与不加种PPV儿童之间无其他统计学显著差异。
  • 携带菌株对青霉素非敏感率45.6%(脑膜炎折点MIC≥0.12 µg/mL),耐药率1.1%(非脑膜炎折点MIC≥8 µg/mL);对复方磺胺甲噁唑 intermediate 耐药23.2%(MIC 1/19-2/38 µg/mL)、完全耐药16.9%(MIC≥4/76 µg/mL)。

关键数值与推荐

  • PCV血清型14和19A对青霉素非敏感率分别为97%和70%,对复方磺胺甲噁唑非敏感率分别为97%和87%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children in Papua New Guinea (PNG) are at high risk of pneumococcal infections. We investigated pneumococcal carriage rates, serotype distribution, and antimicrobial susceptibility in PNG children after vaccination with 10-valent or 13-valent pneumococcal conjugate vaccines (PCV10; PCV13). METHODS: Infants (N = 262) were randomized to receive 3 doses of PCV10 or PCV13 at 1-2-3 months of age, followed by pneumococcal polysaccharide vaccination (PPV) or no PPV at 9 months of age. Nasopharyngeal swabs (NPS) collected at ages 1, 4, 9, 10, 23 and 24 months were cultured using standard bacteriological procedures. Morphologically distinct Streptococcus pneumoniae colonies were serotyped by the Quellung reaction. Antimicrobial susceptibility was determined by Kirby-Bauer disc diffusion and minimum inhibitory concentration (MIC). RESULTS: S. pneumoniae was isolated from 883/1063 NPS collected at 1-23 months of age, including 820 serotypeable (64 different serotypes) and 144 non-serotypeable isolates. At age 23 months, 93.6% (95%CI 86.6-97.6%) of PCV10 recipients and 88.6% (95%CI 80.1-94.4%) of PCV13 recipients were pneumococcal carriers, with higher carriage of PCV10 serotypes by PCV10 recipients (19.8%, 95%CI 12.2-29.5) than PCV13 recipients (9.3%, 95%CI 4.1-17.3) (p = 0.049). There were no other statistically significant differences between PCV10 and PCV13 recipients and children receiving PPV or no PPV. Nearly half (45.6%) of carried pneumococci were non-susceptible to penicillin based on the meningitis breakpoint (MIC ≥ 0.12 µg/mL), but resistance was rare (1.1%) using the non-meningitis cut-off (MIC ≥ 8 µg/mL). Non-susceptibility to trimethoprim-sulfamethoxazole (SXT) was common: 23.2% of isolates showed intermediate resistance (MIC 1/19-2/38 µg/mL) and 16.9% full resistance (MIC ≥ 4/76 µg/mL). PCV serotypes 14 and 19A were commonly non-susceptible to both penicillin (14, 97%; 19A, 70%) and SXT (14, 97%; 19A, 87%). CONCLUSION: Even after PCV10 or PCV13 vaccination, children living in a high-risk setting such as PNG continue to experience high levels of pneumococcal colonization, including carriage of highly antimicrobial-resistant PCV serotypes. The study is registered with ClinicalTrials.gov (CTN NCT01619462).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Orami T, Aho C, Ford RL, et al. Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial. Vaccine. 2023. PMID: 37479616. doi:10.1016/j.vaccine.2023.07.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。